To Evaluate the Safety and Efficacy of TD0015 Pilulae in Patients with Knee Osteoarthritis

Sao Thai Duong

Status and phase: Enrolling; Phase 2

Conditions: Knee Osteoarthritis

Treatments: Drug: TD0015 Placebo; Drug: TD0015

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT06657495

TD0015

Details and patient eligibility

About

Preclinical trials in animal models have suggested that the estimated dose of TD0015 in clinical presents no safety concerns.The investigational product is TD0015 pilulae, which is based on the traditional prescription named "Độc hoạt tang ký sinh thang" (Thien Kim Phuong).

The traditional prescription has the effect of circulating blood in the tendons and bones to bring out evil spirits, blood tonic, kidney tonic to prevent recurrence of diseases and against joint degeneration, joint deformation, muscle atrophy, stiffness to recover normal joint function.

Full description

The study objective is to evaluate the safety and efficacy of TD0015 pilulae to determine the optimal dose for investigational product. Phase II analyzes is performed on 90 patients and based on the results of phase II to adjust sample size and study design (if applicable) for phase III.

The trial lasts for ~ 30 months with 6 subject visits (from T0 to T5) and is conducted in National Hospital of Traditional Medicine (Hanoi, Vietnam).

Screening procedure occurs at T0 visit, followed by T1 (15+/-3 days), T2 (30+/-3 days), T3 (45+/-3 days), T4 (60+/-3 days) and T5 (90+/-3 days). The telephone contact visits are performed every 2 weeks by Investigators There are 2 levels of dosages: estimated dose - 5g (arm 1) and 1.5 times (arm 2) of estimated dose - 7.5g. There is also another arm using placebo, thus the trial have 3 arms in total.

As for 3 arms, patients is allowed to use oral NSAIDs (meloxicam 7,5mg x 1-2 tablets/day) when pain is severe.

Treatment time is 60 days. IP is used after a meal, 1 pack/time x 2 times/day.

Enrollment: 90 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Male or female patients ≥ 18 years old must meet ALL or the following criteria clusters 1,2,6 or 1,3,5,6 or 1,4,5,6 to be enrolled:

1. Knee pain
2. Bone spurs forming along the edges of the joint, narrowing of joint space in X-ray film (grade I-III) according to Kellgren and Lawrence
3. Knee joint effusion
4. Morning stiffness that lasts less than 30 minutes when moving
5. Knee crepitus when moving
6. Patient voluntarily agree and and sign in the ICF

According to traditional medicine: The disease type is Wind-Cold-Damp Bi with Kidney and Liver Deficiency. Symptoms are knee joint is pain, cold and heavy. Pain is usually fixed, little movement, mild during the day, severe at night, increased in cold and wet weather. Warm compresses to relieve pain, knee joint may be swollen, limited movement, may have morning stiffness, joint deformity associated with muscle atrophy, back pain, not warm limbs.The tongue is pale, the tongue is white and greasy, and deep-thready-weak pulse.

Exclusion criteria

1. Hypersensitivity to any subtances of TD0015 pilulae.
2. Pregnant or lactating
3. Currently having surgical indications.
4. Other conditions asseted by the investigator that are not eligible to be enrolled.
5. Knee Osteoarthritis grade IV according to classification of Kellgren and Lawrence (specify that large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends)
6. Self-administration of other anti-inflammatory medicine (except for NSAIDs) during study period as for 3 arms
7. Patient is treated by NSAIDs within 3 days or has corticosteroid Intra-articular injection within 3 months prior to enrolment
8. Joint and/or systemic infections
9. Cardiovascular diseases (arrhythmia, hypertension) without treatment
10. Cross - hypertensitivity to aspirin or other NSAIDs
11. History of recent or progressive peptic ulcer/gastrointestinal perforation
12. Severe liver failure
13. Severe renal failure without dialysis
14. Gastrointestinal hemorrhage, recent brain hemorrhage or disorders causing systemic hemorrhage
15. Uncontrolled heart failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

90 participants in 3 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Placebo pilulae weighing 5g/pack, after a meal, 1pack/time x 2 times/day

Treatment:

Drug: TD0015 Placebo

Investigational product 1

Experimental group

Description:

estimated dose:TD0015 pilulae weighing 5g/pack , after a meal, 1pack/time x 2 times/day

Treatment:

Drug: TD0015

Investigational product 2

Experimental group

Description:

1.5 times of estimated dose: TD0015 pilulae weighing 7.5g/pack , after a meal, 1pack/time x 2 times/day

Treatment:

Drug: TD0015